Ascendis Announces Oral Presentation Of Week 104 Data From Its Pivotal Trial Of Transcon® CNP (Navepegritide) At ISDS 2026
ASND•Ascendis to present week 104 pivotal trial data
- Ascendis Pharma A/S ASND.O announced an oral presentation of week 104 data from its pivotal trial of Transcon® CNP (navepegritide) at ISDS 2026.
Source text: ID:nGNX1YwZB9
